These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

997 related items for PubMed ID: 17869388

  • 1. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
    Eyles JE, Butcher WA, Titball RW, Hill J.
    Vaccine; 2007 Oct 16; 25(42):7301-6. PubMed ID: 17869388
    [Abstract] [Full Text] [Related]

  • 2. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G, Khan AA, Rao DN.
    Scand J Immunol; 2010 Mar 16; 71(3):186-98. PubMed ID: 20415784
    [Abstract] [Full Text] [Related]

  • 3. Immunisation against plague by transcutaneous and intradermal application of subunit antigens.
    Eyles JE, Elvin SJ, Westwood A, Lebutt CS, Alpar HO, Somavarapu S, Williamson ED.
    Vaccine; 2004 Oct 22; 22(31-32):4365-73. PubMed ID: 15474730
    [Abstract] [Full Text] [Related]

  • 4. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague.
    Elvin SJ, Williamson ED.
    Microb Pathog; 2004 Oct 22; 37(4):177-84. PubMed ID: 15458778
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.
    Williamson ED, Flick-Smith HC, Waters E, Miller J, Hodgson I, Le Butt CS, Hill J.
    Microb Pathog; 2007 Jan 22; 42(1):11-21. PubMed ID: 17107769
    [Abstract] [Full Text] [Related]

  • 6. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A, Cohen S, Levy Y, Halperin G, Lazar S, Velan B, Shafferman A, Flashner Y, Mamroud E.
    Vaccine; 2008 Mar 20; 26(13):1616-25. PubMed ID: 18304706
    [Abstract] [Full Text] [Related]

  • 7. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.
    Uppada SB, Bhat AA, Sah A, Donthamshetty RN.
    Vaccine; 2011 Nov 21; 29(50):9352-60. PubMed ID: 22001881
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection.
    Hill J, Leary S, Smither S, Best A, Pettersson J, Forsberg A, Lingard B, Lipka A, Brown KA, Williamson ED, Titball RW.
    Vaccine; 2009 Nov 23; 27(50):7073-9. PubMed ID: 19786138
    [Abstract] [Full Text] [Related]

  • 10. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
    Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW.
    Microb Pathog; 1997 Sep 23; 23(3):167-79. PubMed ID: 9281474
    [Abstract] [Full Text] [Related]

  • 11. Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery.
    Tripathi V, Chitralekha KT, Bakshi AR, Tomar D, Deshmukh RA, Baig MA, Rao DN.
    Vaccine; 2006 Apr 12; 24(16):3279-89. PubMed ID: 16476510
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM, Sambir M, D'Arco C, Peters LA, Seegers JF, Mayer L, McCormick AA, Dattwyler RJ.
    Vaccine; 2016 Nov 11; 34(47):5768-5776. PubMed ID: 27745954
    [Abstract] [Full Text] [Related]

  • 14. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge.
    Palin A, Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK.
    Vaccine; 2007 Jan 08; 25(4):741-50. PubMed ID: 16959385
    [Abstract] [Full Text] [Related]

  • 15. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
    Amemiya K, Meyers JL, Rogers TE, Fast RL, Bassett AD, Worsham PL, Powell BS, Norris SL, Krieg AM, Adamovicz JJ.
    Vaccine; 2009 Apr 06; 27(16):2220-9. PubMed ID: 19428836
    [Abstract] [Full Text] [Related]

  • 16. Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen.
    Garmory HS, Freeman D, Brown KA, Titball RW.
    Vaccine; 2004 Feb 25; 22(8):947-57. PubMed ID: 15161071
    [Abstract] [Full Text] [Related]

  • 17. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
    Williamson ED, Stagg AJ, Eley SM, Taylor R, Green M, Jones SM, Titball RW.
    Vaccine; 2007 Jan 22; 25(6):1142-8. PubMed ID: 17101198
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Small protective fragments of the Yersinia pestis V antigen.
    Vernazza C, Lingard B, Flick-Smith HC, Baillie LW, Hill J, Atkins HS.
    Vaccine; 2009 May 11; 27(21):2775-80. PubMed ID: 19366573
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.